Highly Invasive Fluorescent/Bioluminescent Patient-Derived Orthotopic Model of Glioblastoma in Mice

  • Front Oncol. 2022 Jul 13:12:897839. doi: 10.3389/fonc.2022.897839.
Diana Yuzhakova  1 Elena Kiseleva  1 Marina Shirmanova  1 Vladislav Shcheslavskiy  1  2 Daria Sachkova  3  1 Ludmila Snopova  1 Evgeniya Bederina  1 Maria Lukina  4  1 Varvara Dudenkova  1 Gaukhar Yusubalieva  5  6 Tatyana Belovezhets  7 Daria Matvienko  7 Vladimir Baklaushev  5  6
Affiliations
  • 1. Institute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
  • 2. R&D Department, Becker&Hickl GmbH, Berlin, Germany.
  • 3. Institute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
  • 4. Laboratory of Molecular Oncology, Federal Research and Clinical Center of Physical and Chemical Medicine, Moscow, Russia.
  • 5. Biomedical Research Center, Federal Research and Clinical Center, Federal Medical and Biological Agency, Moscow, Russia.
  • 6. Laboratory of Molecular Mechanisms of Regeneration and Aging, Engelhardt Institute of Molecular Biology, Moscow, Russia.
  • 7. Department of Molecular Immunology, Institute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Abstract

Development of the novel diagnostic and therapeutic approaches in neuro-oncology requires tumor models that closely reproduce the biological features of patients' Tumors. Patient-derived xenografts (PDXs) are recognized as a valuable and the most "close-to-patient" tool for preclinical studies. However, their establishment is complicated by the factors related to both the surgical material and technique of the orthotopic implantation. The aim of this work was to develop a patient-derived Glioblastoma multiform (GBM) model that stably co-expresses luciferase and a far-red Fluorescent protein for monitoring of tumor progression in the brain and, using this model, to validate new diagnostic methods-macroscopic fluorescence lifetime imaging (macro-FLIM) and cross-polarization optical coherence tomography (CP OCT). The established model was similar to the original patient's GBM in terms of histological and immunohistochemical features and possessed reproducible growth in nude mice, which could be observed by both fluorescence and bioluminescence imaging. Our results demonstrated the high potential of macro-FLIM and CP OCT for intraoperative differentiation of GBM from the white matter. Thus, the dual-labeled PDX model of GBM proved to be an excellent approach for observation of tumor development by optical methods.

Keywords
FLIM (fluorescence lifetime imaging microscopy); fluorescence imaging; glioblastoma (GBM); patient-derived xenograft (PDX); primary cell line.